Mucosal surface glycocalyx and associated mucus layer

The mucosal surface glycocalyx and associated mucus layer represent a sophisticated, multi-component extracellular barrier that lines the epithelial surfaces of the respiratory, gastrointestinal, and urogenital tracts (Bansil & Turner, 2018, Advanced Drug Delivery Reviews). The glycocalyx is a dense, membrane-tethered network of glycoproteins and glycolipids that facilitates cell signaling and provides a scaffold for the overlying mucus (Corfield, 2015, Glycoconjugate Journal). The mucus layer itself is a hydrated gel primarily composed of large, secreted, gel-forming mucins that trap pathogens and particulates while providing essential lubrication (Bansil & Turner, 2018). In pathological states such as cystic fibrosis or chronic obstructive pulmonary disease (COPD), mucus becomes hyperviscous and obstructive, whereas in conditions like inflammatory bowel disease (IBD), the barrier is often compromised, leading to increased permeability and inflammation (Corfield, 2015). Pharmacological interventions target this system through mucolytics that break disulfide bonds to reduce viscosity, secretagogues that enhance mucin production, or mucoadhesive polymers designed to prolong drug residence time at the mucosal surface (Sadowska, 2012, Expert Opinion on Drug Safety). Additionally, artificial lubricants and protective agents are used to supplement this layer in conditions like dry eye syndrome or gastritis (Naito et al., 2007, Expert Opinion on Pharmacotherapy). Understanding the structural integrity of this layer is critical for developing effective drug delivery systems and treating barrier-related disorders.

Other names

Mucosal barrierMucus-glycocalyx complexEpithelial glycocalyxMucus layerMucus blanket

Drugs interact with this complex by cleaving disulfide bonds in mucin polymers to reduce viscosity, stimulating the secretion of mucins to enhance barrier thickness, or physically coating the layer to provide lubrication and protection.